Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. reports news tied to its spatial biology business, including spatial proteomics platforms, multiplex immunofluorescence assays and cancer research collaborations. Company updates have covered the PhenoCycler-Fusion platform, PhenoCode Discovery IO60 panel, single-cell spatial proteomics data resources, immuno-oncology studies and biopharma service offerings for biomarker and translational research.
Akoya news also includes operating and financial results, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. In July 2025, Akoya completed a merger and became a wholly owned subsidiary of Quanterix, making its AKYA public-company news record relevant as historical reference for the former Nasdaq-listed issuer.
Akoya Biosciences and NeraCare have entered an exclusive agreement to enhance personalized therapy selection for early-stage melanoma patients. The partnership aims to combine Akoya's PhenoImager HT platform with NeraCare's Immunoprint test to improve access to life-saving therapies for melanoma patients, addressing the critical unmet medical need to identify at-risk patients. The collaboration leverages NeraCare's robust clinical data and Immunoprint's ability to identify high-risk patients, potentially revolutionizing treatment options for early-stage melanoma.
Akoya Biosciences, Inc. has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the increasing demand for its spatial biology solutions. The facility aims to drive operational efficiencies, enhance customer service, and expand the company's portfolio. The 32,000 square foot facility includes R&D, manufacturing, quality control, warehouse space, and distribution, emphasizing cross-functional collaboration and faster product development.
Akoya Biosciences and Shanghai KR Pharmtech have announced that KR-HT5, developed using Akoya's PhenoImager HT technology, has received premarket approval from China's NMPA. This approval will support next generation pathology clinical workflows in China, providing clinicians with a high-throughput platform for multiplex biomarker analysis. Shanghai KR Pharmtech will offer KR-HT5 as part of its Next Generation Pathology solutions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.